share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度報表
美股sec公告 ·  05/15 08:35
Moomoo AI 已提取核心訊息
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
臨床階段生物製藥公司ZyVersa Therapeutics公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲280萬美元，低於去年同期的350萬美元淨虧損。研發費用下降了51.4％，至513,000美元，這主要是由於 IC100 的製造成本降低和工資成本的降低。一般和管理費用也減少了34.6％，至230萬美元，這要歸因於與PIPE股票相關的付款減少，應計獎金減少以及會計費用減少。該公司在本季度末的現金狀況爲200萬美元。ZyVersa專注於開發治療腎臟或炎症性疾病的藥物，尚未從產品銷售中獲得收入。該公司的未來計劃包括繼續其主要候選藥物VAR 200和IC 100的臨床開發，以及尋求額外資金以支持正在進行的運營。
臨床階段生物製藥公司ZyVersa Therapeutics公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲280萬美元，低於去年同期的350萬美元淨虧損。研發費用下降了51.4％，至513,000美元，這主要是由於 IC100 的製造成本降低和工資成本的降低。一般和管理費用也減少了34.6％，至230萬美元，這要歸因於與PIPE股票相關的付款減少，應計獎金減少以及會計費用減少。該公司在本季度末的現金狀況爲200萬美元。ZyVersa專注於開發治療腎臟或炎症性疾病的藥物，尚未從產品銷售中獲得收入。該公司的未來計劃包括繼續其主要候選藥物VAR 200和IC 100的臨床開發，以及尋求額外資金以支持正在進行的運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息